Immunome Inc
NASDAQ:IMNM
Intrinsic Value
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. [ Read More ]
The intrinsic value of one IMNM stock under the Base Case scenario is 1.3 USD. Compared to the current market price of 14.54 USD, Immunome Inc is Overvalued by 91%.
Valuation Backtest
Immunome Inc
Run backtest to discover the historical profit from buying and selling IMNM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Immunome Inc
Current Assets | 144.7m |
Cash & Short-Term Investments | 138.1m |
Other Current Assets | 6.6m |
Non-Current Assets | 3.8m |
PP&E | 3.6m |
Other Non-Current Assets | 200k |
Current Liabilities | 21.8m |
Accounts Payable | 3.3m |
Accrued Liabilities | 8m |
Other Current Liabilities | 10.5m |
Non-Current Liabilities | 6.8m |
Other Non-Current Liabilities | 6.8m |
Earnings Waterfall
Immunome Inc
Revenue
|
14m
USD
|
Operating Expenses
|
-42.7m
USD
|
Operating Income
|
-28.7m
USD
|
Other Expenses
|
-78.1m
USD
|
Net Income
|
-106.8m
USD
|
Free Cash Flow Analysis
Immunome Inc
IMNM Profitability Score
Profitability Due Diligence
Immunome Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Immunome Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
IMNM Solvency Score
Solvency Due Diligence
Immunome Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Immunome Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMNM Price Targets Summary
Immunome Inc
According to Wall Street analysts, the average 1-year price target for IMNM is 36.04 USD with a low forecast of 33.33 USD and a high forecast of 39.9 USD.
Ownership
IMNM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IMNM Price
Immunome Inc
Average Annual Return | -17.32% |
Standard Deviation of Annual Returns | 60.11% |
Max Drawdown | -95% |
Market Capitalization | 868m USD |
Shares Outstanding | 59 694 200 |
Percentage of Shares Shorted | 6.45% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 39 full-time employees. The company went IPO on 2020-10-02. The firm's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The firm is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.
Contact
IPO
Employees
Officers
The intrinsic value of one IMNM stock under the Base Case scenario is 1.3 USD.
Compared to the current market price of 14.54 USD, Immunome Inc is Overvalued by 91%.